Cuprina Holdings (Cayman) Ltd与Aiodine实验室联合成立合资公司,旨在开发和营销新型碘基溶液,以作为创伤护理的新疗法。Cuprina Holdings (Cayman) Ltd计划于2026年开展临床研究,以获取监管批准。
Cuprina Holdings (Cayman) Ltd与Aiodine实验室联合成立合资公司,旨在开发和营销新型碘基溶液,以作为创伤护理的新疗法。Cuprina Holdings (Cayman) Ltd计划于2026年开展临床研究,以获取监管批准。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.